Partnership accelerates AGC Biologics' leadership in the AAV market, applying its BravoAAV™ platform to complex gene therapies for inherited blindness MILAN--(BUSINESS WIRE)-- On the heels of ...
From rare diseases to common chronic conditions, advances in viral vector-based gene therapies are bringing exciting new clinical possibilities to the table. But current costs per dose land as high as ...
Patients in a Phase I/II clinical trial conducted by UMass Chan Medical School of a dual vector gene therapy for GM2 gangliosidosis, which includes Tay-Sachs and Sandhoff diseases, exhibited a ...
LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell” or the “Company”), a specialist viral vector Contract Development and Manufacturing Organisation (“CDMO”) for cell and gene therapy ...
Viral vector-based gene therapies hold immense promise for treating a multitude of diseases. However, their widespread adoption has been hindered by inefficient manufacturing methods and the absence ...
Viral vectors are engineered viruses that are used to deliver genetic material into cells for various applications, such as gene therapy, vaccine development, and biotechnology research. These viruses ...
Viral vectors are a key component of many advanced gene therapies and vaccines, but reliable, large-scale manufacturing remains a significant challenge. Continued innovation in vector design, cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results